Growth Metrics

Scholar Rock Holding (SRRK) Total Non-Current Liabilities (2017 - 2021)

Scholar Rock Holding's quarterly Total Non-Current Liabilities came in at $115.4 million in Q2 2021, down 3.87% quarter-over-quarter from $120.0 million in Q1 2021.

Scholar Rock Holding has reported Total Non-Current Liabilities for 4 years, with the latest figure at $115.4 million in Q2 2021.

  • For the quarter ending Q2 2021, Total Non-Current Liabilities changed N/A year-over-year to $115.4 million; the trailing twelve-month figure through Jun 2021 stood at $115.4 million (changed N/A YoY), and the FY2020 full-year result was $127.5 million, up 52.78% from the prior year.
  • Total Non-Current Liabilities for Q2 2021 stood at $115.4 million, down from $120.0 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $127.5 million in Q4 2020, with the low at $5.9 million in Q4 2017.
  • Average Total Non-Current Liabilities over 4 years is $90.5 million, with a median of $115.4 million recorded in 2021.
  • Peak annual rise in Total Non-Current Liabilities reached 52.78% in 2020, while the deepest fall reached 52.78% in 2020.
  • Tracing SRRK's Total Non-Current Liabilities over 4 years: stood at $5.9 million in 2017, then jumped by 1317.16% to $83.5 million in 2019, then surged by 52.78% to $127.5 million in 2020, then retreated by 9.52% to $115.4 million in 2021.
  • The last three Total Non-Current Liabilities figures came in at $115.4 million (Q2 2021), $120.0 million (Q1 2021), and $127.5 million (Q4 2020), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 11.03 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 42,980.09
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 95.20 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 110.28 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 5.87 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 7.32 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 4.05 Bn
10 Scholar Rock Holding 500.61 Mn 20.67 Mn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2021 115.39 Mn
Mar 31, 2021 120.04 Mn
Dec 31, 2020 127.53 Mn
Dec 31, 2019 83.47 Mn
Dec 31, 2017 5.89 Mn